| Code | CSB-RA011664MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Gerilimzumab, targeting interleukin-6 (IL-6), a pleiotropic pro-inflammatory cytokine central to immune regulation and acute phase responses. IL-6 plays critical roles in B-cell differentiation, T-cell activation, and hepatocyte stimulation, while also mediating fever and inflammatory responses. Dysregulated IL-6 signaling is implicated in numerous pathological conditions including rheumatoid arthritis, cytokine release syndrome, Castleman's disease, and various malignancies where it promotes tumor growth, angiogenesis, and therapeutic resistance.
Gerilimzumab is a humanized IgG1 monoclonal antibody that binds IL-6 with high affinity, neutralizing its biological activity by preventing interaction with IL-6 receptors. This biosimilar antibody provides researchers with a valuable tool for investigating IL-6-mediated signaling pathways, studying inflammatory disease mechanisms, and exploring therapeutic intervention strategies in preclinical models. It enables examination of IL-6 blockade effects on cellular responses, cytokine networks, and disease progression across immunology, oncology, and inflammation research.
There are currently no reviews for this product.